SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has signed an option agreement with Leland Stanford Junior University (“Stanford”) that will add proprietary technology to the Company’s programs.
“We look forward to working with Stanford to develop their technology,” said George Tidmarsh, President and CEO of La Jolla. “As we continue to expand our product portfolio, we remain committed to helping patients who suffer from severe diseases for which no treatment is available.”
The option agreement with Stanford allows La Jolla to test the technology potentially adding important and diversified product opportunities to La Jolla’s pipeline. La Jolla is currently testing novel oral formulations using the technology in an animal model of Non-alcoholic Steatohepatitis (NASH). If successful, these product candidates will add to the company’s growing pipeline that includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload, and rare diseases.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company’s second product candidate, is a natural peptide for the treatment of hepatorenal syndrome. LJPC-401 (hepcidin) is in preclinical development for iron overload conditions. For more information on the Company please visit http://www.ljpc.com.
Forward Looking Statement Safe Harbor
This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings with the U.S. Securities and Exchange Commission (“SEC”), all of which are available free of charge on the SEC's web site http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100 and LJPC-501, the success and timing of future preclinical and clinical studies of these compounds, and potential indications for which GCS-100 and LJPC-501 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.